Publication | Closed Access

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Metabolic SyndromeDiabetes ManagementDiabetesPharmacologyType 2PharmacotherapyNovel Dual GipDiabetes MellitusMedicineGlp-1 Receptor Agonist